HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells
about
Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancerVersican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapyVersican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling.Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasisEGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversificationEffect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts.Role of traditional and new biomarkers in breast carcinogenesis.Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancerLapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.EGFR juxtamembrane domain, membranes, and calmodulin: kinetics of their interaction.Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cellsNeratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors.Human epidermal growth factor receptor dimerization analysis in breast cancer diagnosis: potential for improving testing accuracy and treatment selection.The challenges of integrating molecular imaging into the optimization of cancer therapy.The Potential of panHER Inhibition in Cancer.HER3/ErbB3, an emerging cancer therapeutic target.Docosahexaenoic Acid Downregulates EGF-Induced Urokinase Plasminogen Activator and Matrix Metalloproteinase 9 Expression by Inactivating EGFR/ErbB2 Signaling in SK-BR3 Breast Cancer Cells.Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyAnalysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers.Synergistic enhancement of the potency and selectivity of small molecule transcriptional inhibitorsFEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells.Cancer stem cell, niche and EGFR decide tumor development and treatment response: A bio-computational simulation studyHER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies.EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.Crosstalk between ERα and Receptor Tyrosine Kinase Signalling and Implications for the Development of Anti-Endocrine Resistance.
P2860
Q27853060-616A394A-956C-431D-8872-B12CEC85865FQ28476604-63FD3EFF-124F-4B9D-AAED-6CC64AFAA7FEQ28477876-22930FD4-B1C4-4727-B709-E06C312B1CDAQ33747782-FA162E74-E1B5-4EAC-B83F-C6F9A3549B24Q33867316-882B3DB0-D238-4C34-89ED-20D74164ABDDQ34296575-557D02A2-757F-4141-BC38-577226878E5BQ34334333-B107F869-796E-46A6-9D19-1BD2D4BAF892Q34545157-217E0805-AD7B-415A-940E-13050BDBF243Q34613543-50B6A969-4051-4FD3-A085-A916ED541A13Q34722687-217C30EA-7C4F-4741-B819-6B753B358E5EQ34740289-1A43DBB1-0247-4AC1-89DE-40E0796249F6Q35572905-812646AE-FC36-4A08-8725-1FB63967226CQ35742383-3F6CB9BB-55B4-4B59-8299-A5304860AD4DQ35913109-9C345A34-1282-4257-8734-0B174D26BD18Q36412836-AB651E73-C41D-4EEE-AFD1-807071C76887Q37205574-9D080A4A-957E-4E1A-941B-2914B95E1A18Q37265362-D8152BD1-7744-4B43-B837-89BD16A56751Q37330777-C2F83AB7-BFCB-4E0F-B761-42A39251AAA2Q37381579-38570A23-3825-4CB7-B271-2843CBC59AEEQ37628728-C0DD8315-97AD-48C3-A371-8227A32C9C9BQ37635099-0F102A33-3BBA-4998-AE15-A1F87CCCE75CQ37871875-1741C69B-E677-41E5-993F-E54185857091Q38352587-91E57DBB-C427-46F1-8E7B-2EC3F7F09EF8Q38615197-0DA7B825-13DD-4ACB-8475-E7B3B3D3F93FQ38875428-44381EEC-C803-4213-B3F5-92F0945BF613Q38945259-7952C04A-DDF8-40EC-87C6-16AB0EEC0408Q39308117-6CD76A17-E130-435C-A460-96CB4603972CQ39421577-657E3F59-FABB-4A6A-9E21-9659FB2047D4Q39475977-A106E8B4-B1E1-4A0A-8DEF-17DED90A056CQ41470556-586BB6EB-15CC-4C72-AF67-B0B2B378DC7BQ41623719-47B3C966-DC5B-4509-AF8D-73FE46E9EAACQ41868891-679B2446-9F1C-4AE9-B45D-AD61CF56DAE7Q42104011-20D08C25-A8F3-4276-AACE-2DA5748041CCQ47111722-E8D4545E-5534-40C5-A59F-F832420EC2AEQ47600932-2256B39B-1908-40B1-8020-608325AAA1F2Q55496875-DD9BEF8C-1CC1-4535-8740-B450107B49D2
P2860
HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
HER2 oncogenic function escape ...... ceptors in breast cancer cells
@ast
HER2 oncogenic function escape ...... ceptors in breast cancer cells
@en
HER2 oncogenic function escape ...... ceptors in breast cancer cells
@nl
type
label
HER2 oncogenic function escape ...... ceptors in breast cancer cells
@ast
HER2 oncogenic function escape ...... ceptors in breast cancer cells
@en
HER2 oncogenic function escape ...... ceptors in breast cancer cells
@nl
prefLabel
HER2 oncogenic function escape ...... ceptors in breast cancer cells
@ast
HER2 oncogenic function escape ...... ceptors in breast cancer cells
@en
HER2 oncogenic function escape ...... ceptors in breast cancer cells
@nl
P2093
P2860
P50
P1433
P1476
HER2 oncogenic function escape ...... ceptors in breast cancer cells
@en
P2093
Anthony Kong
Pierre Leboucher
Véronique Calleja
P2860
P356
10.1371/JOURNAL.PONE.0002881
P407
P577
2008-08-06T00:00:00Z